Equities Analysts Set Expectations for Evolent Health Inc’s Q1 2020 Earnings (NYSE:EVH)

Evolent Health Inc (NYSE:EVH) – Stock analysts at William Blair issued their Q1 2020 EPS estimates for Evolent Health in a report released on Tuesday, November 5th. William Blair analyst R. Daniels forecasts that the technology company will post earnings per share of ($0.10) for the quarter. William Blair also issued estimates for Evolent Health’s Q2 2020 earnings at ($0.10) EPS, Q3 2020 earnings at ($0.05) EPS and Q4 2020 earnings at ($0.02) EPS.

Evolent Health (NYSE:EVH) last announced its earnings results on Tuesday, November 5th. The technology company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.03. The company had revenue of $220.14 million during the quarter, compared to analyst estimates of $217.90 million. Evolent Health had a negative net margin of 15.02% and a negative return on equity of 6.87%. Evolent Health’s revenue was up 46.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.04) earnings per share.

Several other research analysts have also weighed in on EVH. Cantor Fitzgerald set a $16.00 target price on shares of Evolent Health and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Piper Jaffray Companies increased their target price on shares of Evolent Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a research note on Wednesday. ValuEngine raised shares of Evolent Health from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Cowen set a $18.00 price target on shares of Evolent Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Oppenheimer set a $15.00 price target on shares of Evolent Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $15.75.

EVH stock traded up $0.79 during mid-day trading on Friday, hitting $10.12. 1,856,677 shares of the company were exchanged, compared to its average volume of 1,365,906. The company has a quick ratio of 1.39, a current ratio of 1.39 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $676.14 million, a P/E ratio of -28.91 and a beta of 1.07. The business has a fifty day simple moving average of $7.57 and a 200-day simple moving average of $8.80. Evolent Health has a 12-month low of $5.50 and a 12-month high of $26.96.

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Evolent Health by 9.1% in the second quarter. Vanguard Group Inc. now owns 6,570,526 shares of the technology company’s stock valued at $52,236,000 after acquiring an additional 548,064 shares in the last quarter. BlackRock Inc. raised its holdings in Evolent Health by 5.9% in the second quarter. BlackRock Inc. now owns 5,073,428 shares of the technology company’s stock valued at $40,334,000 after acquiring an additional 282,951 shares in the last quarter. Riverbridge Partners LLC raised its holdings in Evolent Health by 0.7% in the third quarter. Riverbridge Partners LLC now owns 3,428,455 shares of the technology company’s stock valued at $24,651,000 after acquiring an additional 24,929 shares in the last quarter. Eagle Asset Management Inc. raised its holdings in Evolent Health by 62.1% in the third quarter. Eagle Asset Management Inc. now owns 3,002,480 shares of the technology company’s stock valued at $21,587,000 after acquiring an additional 1,149,789 shares in the last quarter. Finally, Carillon Tower Advisers Inc. raised its holdings in Evolent Health by 71.5% in the third quarter. Carillon Tower Advisers Inc. now owns 2,801,065 shares of the technology company’s stock valued at $20,140,000 after acquiring an additional 1,167,612 shares in the last quarter. 95.15% of the stock is currently owned by hedge funds and other institutional investors.

In other Evolent Health news, Director Kenneth A. Samet purchased 7,200 shares of Evolent Health stock in a transaction dated Thursday, August 15th. The shares were acquired at an average price of $7.04 per share, with a total value of $50,688.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Doug S. Aron purchased 10,550 shares of Evolent Health stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average cost of $8.20 per share, for a total transaction of $86,510.00. 4.50% of the stock is currently owned by corporate insiders.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Recommended Story: What are the Benefits of Index Funds?

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.